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Abstract Immune reconstitution has improved outcomes
for progressive multifocal leukoencephalopathy (PML), a
potentially lethal brain disease caused by JC virus (JCV).
However, an antiviral treatment to control JCV is needed
when immune reconstitution is delayed or not possible. On
the basis of in vitro efficacy, this study evaluated the effect
of mefloquine on PML and factors that may predict PML
outcomes. This 38-week, open-label, randomized, parallel-
group, proof-of-concept study compared patients with PML
who received standard of care (SOC) with those who re-
ceived SOC plus mefloquine (250 mg for 3 days, then
250 mg weekly). Patients randomized to SOC could add
mefloquine treatment at week 4. The primary endpoint was
change from baseline to weeks 4 and 8 in JCV DNA copy
number (load) in cerebrospinal fluid (CSF). Exploratory
analyses evaluated factors that might correlate with clinical
outcome. The majority of enrolled patients were HIV posi-
tive. Preplanned interim data analyses suggested that the
study was unlikely to successfully demonstrate a significant
difference between groups; therefore, the study was termi-
nated prematurely. There was no significant difference
between groups in CSF JCV DNA loads or clinical/MRI
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findings. Decrease in CSF JCV DNA load from baseline to
week 4 was associated with a better clinical outcome at
16 weeks, as measured by Karnofsky scores. This study
found no evidence of anti-JCV activity by mefloquine. An
early decrease of CSF JCV DNA load appears to be associ-
ated with a better clinical outcome.
Keywords Mefloquine . Leukoencephalopathy . Progressive
multifocal . JC virus .Magnetic resonance imaging
Introduction
Progressive multifocal leukoencephalopathy (PML) is a se-
rious brain infection caused by lytic JC virus (JCV) infec-
tion of oligodendrocytes and astrocytes in the human brain
(Tan and Koralnik 2010; Brew et al. 2010; Ferenczy et al.
2012). PML occurs primarily in the setting of immune
dysfunction, most commonly in untreated patients with ad-
vanced human immunodeficiency virus (HIV) infections,
but also in the setting of malignancies, organ transplanta-
tion, and autoimmune diseases treated with certain immu-
nomodulatory agents, including natalizumab. In untreated
HIV patients, PML generally is rapidly fatal within months
of diagnosis (Koralnik 2006).
With successful immune reconstitution, such as with
highly active antiretroviral therapy (HAART) for pa-
tients with HIV infection, the prognosis for patients
with PML has substantially improved (Berger 2011).
However, direct antiviral therapy is needed for situations
where immune reconstitution is difficult to achieve or
delayed. Additionally, JC viral control entirely by im-
mune reconstitution carries with it risk of “bystander”
brain damage from excess immune responses that might
be minimized by use of antiviral therapy. Thus far, there
has been no such antiviral agent with proven efficacy
despite anecdotal reports regarding various agents (Brew
et al. 2010).
Mefloquine is a drug that has been used extensively for
prophylaxis and treatment of malaria (Roche Laboratories Inc.
2003). Previously, an in vitro model of JCV infection of human
astrocytes was used to screen several thousand available drugs
for activity against JCV. Mefloquine was found to inhibit JCV
infection and replication in concentrations generally achieved
in brains of patients given mefloquine for malaria
(Brickelmaier et al. 2009). This activity included the ability
to inhibit infection with JCV strains typically causing PML.
Since there is no animal model available with which to
study PML effectively (Brickelmaier et al. 2009) and meflo-
quine has a long and substantial history of use and generally
favorable record of safety in humans (Schlagenhauf et al.
2010), it was decided to undertake a clinical trial seeking
evidence of clinical activity of mefloquine in patients with
PML, without further in vitro or animal studies. The clinical
trial also provided a rare opportunity to systematically study
factors that may be predictive of patient outcomes in PML,




An open-label, rater-blinded, randomized, parallel-group
treatment trial comparing a group receiving only local
standard-of-care (SOC) therapy for PML (which could in-
clude any treatment or procedure that the investigator would
normally use to treat PML; hereafter referred to as “SOC” or
“control” group) with a group receiving both SOC and
mefloquine (250 mg daily for 3 days, then weekly; hereafter
referred to as “mefloquine group”) was undertaken (Fig. 1).
The primary endpoint was the change from baseline to
weeks 4 and 8, respectively, in JCV DNA load in the
cerebrospinal fluid (CSF).
The SOC group was given the option to receive meflo-
quine treatment beginning at week 4 (or week 8 in early
versions of the protocol). The planned duration of the study,
including screening, 24 weeks of treatment, and follow-up,
was 38 weeks. Patients with PML were recruited at 13 study
sites [US (five sites), Germany (three sites), Spain (two
sites), Italy (one site), Australia (one site), and Brazil (one
site)]. The study protocol and consent forms were approved
by the institutional review boards/ethics committees associ-
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Fig. 1 Trial design. Asterisk In
an earlier version of the protocol,
patients could cross over to SOC
+ mefloquine at week 8. The
final protocol allowed this option
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Patients
Eligible patients were men or women with PML, be-
tween 18 and 75 years of age. Other eligibility criteria
included weight ≥30 kg, confirmation of PML diagnosis
by JCV DNA detection in CSF, onset of PML symp-
toms within 6 months of randomization, and anticipated
survival of ≥2 months. Concomitant opportunistic cen-
tral nervous system infections or unexplained epileptic
seizures within 6 months pre-randomization were exclu-
sionary. Both HIV-positive and HIV-negative patients
were included. HIV-positive patients received antiretroviral
therapy as SOC.
Assessments
JCV DNA copy number in the CSF was measured at screen-
ing and at 4, 8, 16, and 24 weeks at a central laboratory,
Focus Diagnostics, Inc. (Cypress, CA, USA). The lower
limit of quantitation was 50 copies/mL. Other laboratory
values including CD3+/CD4+ fluorescence-activated cell
sorter (FACS) count, CD3+/CD8+ FACS count, Cylex®
(Cylex Inc., Columbia, MD, USA) stimulated adenosine
triphosphate (ATP), and HIV RNA polymerase chain reac-
tion (PCR) were evaluated at screening and at every regu-
larly scheduled study visit. Serum mefloquine levels were
measured throughout the treatment period; mean steady-
state levels were modeled relative to JCV DNA levels in
the CSF. Plasma concentrations of mefloquine and
carboxymefloquine, determined by mass spectroscopy (mef-
loquine assay and carboxylic acid assay), were measured at
baseline and at weeks 4, 8, 16, and 24. Brain mefloquine
concentration in the frontal lobe was measured in the case of
one patient who died 2 days after mefloquine dosing.
Clinical efficacy measures included the Karnofsky
Performance Scale Index (KPSI), Expanded Disability
Status Scale (EDSS), and the Symbol Digit Modalities
Test (SDMT) at baseline and at 4, 8, 16, and 24 weeks.
A Visual Analogue Scale (VAS), with which the patient
indicated his/her impression of overall well-being, was
included at screening and at every regularly scheduled
visit.
Brain MRI scans were performed at baseline and at
4, 8, 16, and 24 weeks, and image analyses were at the
Buffalo Neuroimaging Analysis Center, University of
Buffalo, New York. MRI sequences included 2D multi-
planar dual fast spin-echo proton density and T2-weighted
image (WI), fluid-attenuated inversion-recovery, and spin echo
T1-WI both with andwithout a single-dose intravenous bolus of
0.1 mmol/kg gadolinium (Gd)–diethylenetriaminepentaacetic
acid with scanning 5 min after injection. The “Electronic
Supplementary Material” gives a more detailed descrip-
tion of MRI sequences.
T2, T1, and gadolinium-enhancing (Gd+) lesion vol-
umes (LVs) in areas suggestive of PML were calculated
using a semi-automated edge-detection contouring-
thresholding technique, as previously described
(Zivadinov et al. 2001). Non-serious adverse events,
serious adverse events, and concomitant therapy were
monitored on an ongoing basis. An independent safety
monitoring committee was appointed to provide safety
oversight for the study. Mortality was assessed through-
out the study.
Statistical analysis
The population for efficacy analysis consisted of all patients
who had a measurable JCV DNA load in CSF at screening
from the central laboratory. The patients were stratified into
three groups: (1) HIV-positive, HAART-naïve patients (n=
24); (2) HIV-positive patients with a history of HAART (n=
5); and (3) HIV-negative patients (n=8). Patients who
switched to mefloquine treatment at week 4 or week 8 were
counted in both comparison groups (SOC vs mefloquine).
All patients who entered the study and had a postbaseline
safety assessment were included in the safety analyses. The
population for pharmacokinetic analysis consisted of all
patients who received mefloquine and had at least one
measurable mefloquine concentration. The study was
powered to detect at least 1 log difference in JCV load
between treatment groups, but not to detect differences in
other measures.
Results of clinical and laboratory/imaging evaluations
were expressed as mean values ± standard deviation
(SD), unless otherwise noted. The Student’s t test was
used to analyze the change from baseline to week 4
(and week 8 in a sensitivity analysis) on the log-
transformed JCV DNA level in CSF and MRI T2/T1
LVs as well. The Wilcoxon rank-sum test was used to
analyze the changes in other endpoints including EDSS,
KPSI, and SDMT. For patients who died, EDSS or
KPSI scores at the time of death and up to week 24
were imputed to 10.0 or 0, respectively (EDSS score of
10.0 or KPSI score of 0 signifies death). The Fisher
exact test was used to analyze MRI Gd activity and
mortality.
As there was no difference detected between the
mefloquine and SOC control groups on any measure,
data were pooled for post hoc analyses to explore
factors that may predict clinical outcome in patients
with PML. Only data from HIV-positive patients were
used for these exploratory analyses. The last observa-
tion carried forward (LOCF) method was used to im-
pute the missing values for KPSI, and its change from
baseline to week 16 was calculated. A categorical form
of KPSI was then defined as improvement (increase in
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score >1), deterioration (decrease in score >1), or stable
(patients who did not meet improvement or deteriora-
tion criteria).
The following variables of interest were tested for
their potential correlation or association to KPSI change
from baseline to week 16; except where specified, both
baseline and change from baseline at week 4 results
were tested: KPSI score (<50 vs ≥50, baseline only),
EDSS score (<6.0 vs ≥6.0, baseline only), log10 JCV
DNA load in CSF, log10 JCV DNA load in plasma,
log10 JCV DNA load in urine, CD3
+/CD4+ FACS count,
CD3+/CD8+ FACS count, Cylex® stimulated ATP, HIV
RNA PCR, presence of Gd + lesions, T2 volume,
SDMT, and VAS. The Pearson correlation coefficient
was calculated to evaluate relationships between vari-
ables. Logistic regression was used to explore the asso-
ciation between KPSI score and the variables of interest.
The Fisher exact test was performed if there were issues
of separation for binary variables, such as EDSS score
<6.0 vs ≥6.0 at baseline.
Results
Patients
Patient characteristics are presented in Table 1. Thirty-seven
patients were randomized (29 HIV-positive and 8 HIV-
negative patients) to SOC or mefloquine. Only 12 of the
37 patients who were randomized and dosed completed
study treatment.
The study was terminated prematurely upon recom-
mendation by the Data Safety Committee as ongoing
data monitoring allowed conditional power calculations
that suggested a very small probability of the study
demonstrating any difference in the primary endpoint in
this small study population. Calculations suggested that
even if the study could have been extended to allow for
a much larger patient population, it remained unlikely
that a difference could be demonstrated.
Twenty-two serious adverse events were reported, pre-
dominantly associated with progressing neurological dis-
ability or death. None was believed to be associated with
administration of mefloquine. Deaths were disproportion-
ately represented in the HIV-negative group (four deaths
among eight randomized patients, 50 %) vs HIV-positive
group (four deaths among 29 randomized patients, 14 %).
Many of the deaths occurred early in the trial, making
attribution of findings to assigned therapy problematic.
Results of the mefloquine study and exploratory analyses
reported hereafter are limited to results in HIV-positive
patients (both HAART-naïve patients and those with a
history of receiving HAART), as meaningful analysis of
data from HIV-negative patients was limited by the
small number of patients, as well as by the early and
high mortality in this group.














Number of patients dosed 7 5 5 20 37
Disease history, n (%) HAART naïve 3 (43) 5 (100) 3 (60) 13 (65) 24 (65)
History of HAART 1 (14) 0 1 (20) 3 (15) 5 (14)
HIV negative 3 (43) 0 1 (20) 4 (20) 8 (22)
JCV DNA titer (in CSF)
at screening (copies/mL),
n (%)
≤50 0 0 0 4 (20)a 4 (11)a
>50 7 (100) 5 (100) 5 (100) 15 (75) 32 (86)
Missing 0 0 0 1 (5) 1 (3)
Gender male, n (%) Male 6 (86) 3 (60) 3 (60) 15 (75) 27 (73)
Race, n (%) Black or African
American
1 (14) 2 (40) 2 (40) 4 (20) 9 (24)
White 6 (86) 3 (60) 3 (60) 16 (80) 28 (76)
Age (years), mean (SD) 48.7 (20.56) 41.6 (11.37) 47.4 (10.06) 48.1 (9.40) 47.2 (12.16)
Weight (kg), mean (SD) 71.31 (14.83) 60.12 (12.75) 75.54 (22.88) 65.71 (15.52) 67.34 (16.16)
HAART highly active antiretroviral therapy, HIV human immunodeficiency virus, JCV JC virus, SD standard deviation, SOC standard of care
All patients (n=7) in the “randomized to SOC alone” column discontinued study treatment; of the remaining patients, those who were not
randomized to receive SOC + mefloquine at the start of the study opted to be treated with mefloquine at week 4 or week 8. No patients remained on
SOC alone throughout the study
a Patients enrolled based on local laboratory data; in some instances, the results were not replicated by the central laboratory
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CSF JCV DNA
Baseline CSF JCV DNA levels (log10 copies per milliliter)
were the same in the SOC (n=13; mean 3.7, SD 1.18) and
the mefloquine groups (n=19; mean 3.7, SD 1.24). Mean
CSF JCV DNA values at each time point were similar for
the SOC and the mefloquine groups (Fig. 2). Overall
mean changes in JCV DNA in CSF viral loads did not
differ significantly between mefloquine and control
groups at week 4 (SOC=−0.46±0.60 vs mefloquine=
0.04±1.54; p=0.2972).
Exploratory analyses revealed that reductions in JCV
DNA load in CSF at week 4 were significantly associated
with improvement in KPSI at week 16 (the clinical outcome
measure for the exploratory analyses; Table 2). This associ-
ation was maintained at weeks 8 and 16 (Fig. 3). In contrast,
JCV DNA loads in CSF at baseline and changes at week 4
did not correlate with KPSI values at other time points
besides week 16.
Other clinical and laboratory variables
Mean KPSI scores at both weeks 4 and 8 were also
(unexpectedly) higher in the SOC group (Fig. 4). Mean
change in KPSI scores was significantly higher in the SOC
group than in the mefloquine group at week 4 (SOC=5.56±
7.27 vs mefloquine=−5.56±11.50; p=0.0050); however,
this difference was not sustained to week 8 (SOC=7.5±
12.58 vs mefloquine=−6.4±16.46; p=0.1190). Also,
the study was not powered to detect differences between
treatment groups in other measures besides difference in
JCV load.
Mean EDSS scores were higher in the SOC group than in
the mefloquine group (Fig. 5). Mean changes in EDSS score
from baseline were not significantly different between mef-
loquine and control groups at week 4 (SOC=0.39±0.74 vs
mefloquine=0.31±1.02; p=0.6190) or week 8 (SOC=
−0.63±0.95 vs mefloquine=0.64±1.23; p=0.0588).
Although the sample size was small and diminished
over time (N=24 at baseline and N=14 by week 15;
weeks 20 and 24 not included in analyses), EDSS and
KPSI values were correlated at baseline and at weeks 4,
8, and 16 (Pearson correlation coefficient [r] 0.768,
0.719, 0.792, and 0.858, respectively) (Supplementary
Figure 1). Compared with their actual values, KPSI
and EDSS changes from baseline were not as highly
correlated at weeks 4, 8, and 16 (data not shown).
Other clinical or laboratory variables at baseline or the
change in their value from baseline to week 4 did not show
any notable correlation to the clinical outcome measure
(Table 2). Sensitivity binary analyses done by dividing the
clinical outcome measure into those improving, remaining
stable, or deteriorating on KPSI at week 16 did not reveal
any additional information.
Brain MRI findings
There were no significant differences in MRI findings
between mefloquine-treated patients and control patients
either at baseline or following randomization. MRI
showed Gd+lesions at baseline in eight of 18 (44 %)
patients who received mefloquine and in six of 11
(55 %) control patients; at week 4, in eight of 12
(67 %) patients who received mefloquine and in five
of ten (50 %) control patients; at week 8, and in seven
of 11 (64 %) patients who received mefloquine and in
one of four (25 %) control patients. There were no
significant differences in the change from baseline to
subsequent time points in T1, T2, or Gd + LVs between
mefloquine and control groups. There was no significant
relationship between MRI parameters and the clinical
outcome measure (Table 2).
Discussion
Mefloquine did not show evidence of in vivo antiviral
activity against JCV as evaluated by JCV DNA load in
CSF. While the study was specifically designed to mea-
sure differences in JCV load between patients treated
with mefloquine and patients treated with SOC, there
also did not appear to be any mefloquine effect on
clinical disability, MRI parameters, or survival in com-
parison with SOC. Lack of efficacy likely was not
because of inability to achieve therapeutic concentration



































Fig. 2 Mean (± SD) JCV DNA load in CSF in all HIV-positive
patients (HAART-naïve and history of HAART groups combined).
HIV-negative patients not included in analysis. Patients in the SOC
group who opted to receive mefloquine at week 4 were not counted in
the week 8 results. CSF cerebrospinal fluid, HAART highly active
antiretroviral therapy, HIV human immunodeficiency virus, JCV JC
virus, SOC standard of care
J. Neurovirol. (2013) 19:351–358 355
of mefloquine; in one patient who received mefloquine
2 days prior to death, brain mefloquine concentration
was measured at 84 μM at autopsy.
It is important to note that only 12 of the 37 patients who
were randomized and dosed completed study treatment;
therefore, the data are limited. Because of the small number
of patients with non-HIV-related PML included in this study
and because of the early deaths in this arm, it was not
possible to do a meaningful analysis of patients who were
not HIV positive. The results therefore reflect PML in the
setting of HIV disease.
The mortality rate for HIV-positive patients in the study
was approximately 14 %, which is better than most histor-
ical reports (Gasnault et al. 2011) but also reflects a shorter
time frame than do many reports. The rate also only reflects
patients who completed the study; many patients did not
finish the study period because of study termination or
premature withdrawal and/or disease progression (thus, it
is possible the mortality rate over a more extended period
would be higher than 14 %). In light of apparent lack of
mefloquine treatment effect on PML, the data were explored
for information that might be associated with clinical out-
comes in PML patients.
In the analysis of the association between the clinical
outcome measure and various variables of interest, most
were not significant. However, decreasing JCV DNA load
in CSF as early as week 4 was correlated with better clinical
outcome, consistent with earlier findings that demonstrated
a marked decrease in JCV DNA levels over time in
HAART-treated patients in whom the PML disease course
stabilized (Bossolasco et al. 2005; Delbue et al. 2012).
Contrary to what might be expected, neither CD4+
cell counts nor serum HIV RNA titers at baseline were
associated with the clinical outcome in this HIV-positive
population. This likely reflects the availability of active
HIV therapies capable of initiating immune reconstitu-
tion in most AIDS patients in the current era.
The small number of evaluable patients in this trial reflects
the logistical and technical challenges inherent in PML clini-
cal trials. While larger trials are needed to reach definitive
conclusions, experience thus far indicates that it will be very
challenging to enroll a sufficient number of PML patients in
clinical trials. Also, the frequently rapid speed of PML disease
progression may complicate attempts to monitor treatment
effects over time in studies of this nature. Finally, the success
of antiretroviral treatments, especially in the modern era, may
Table 2 Explorations of potential predictors of clinical deterioration at week 16 as measured by change in KPSI to week 16
Baseline Change at week 4
Variable of interest N OR (95 % CI) N OR (95 % CI)
CD3+/CD4+ FACS count (mm3) 14 0.999 (0.993 to 1.005) 10 0.983 (0.949 to 1.017)
CD3+/CD8+ FACS count (mm3) 14 1.002 (0.998 to 1.005) 10 1.006 (0.997 to 1.016)
Cylex stimulated ATP (ng/mL) 12 0.989 (0.978 to 1.001) 8 1.002 (0.985 to 1.020)
EDSS score (<6, ≥6) 14 2.715 (0.363 to 20.292) 14 N/A
HIV RNA PCR (copies/mL) 10 1.000 (1.000 to 1.000) 6 1.000 (0.999 to 1.002)
KPSI score (<50, ≥50) 14 3.000 (0.392 to 22.933) 14 N/A
Presence of Gd + lesions 12 5.000 (0.520 to 48.066) 9 0.291 (0.016 to 5.231)
SDMT score 10 1.041 (0.927 to 1.169) 6 1.062 (0.806 to 1.398)
T2 lesion volume (mm3) 13 1.000 (1.000 to 1.000) 9 1.000 (1.000 to 1.000)b
VAS score 13 1.003 (0.974 to 1.032) 10 1.015 (0.984 to 1.048)
Log10 (JCV DNA in CSF) (copies/mL) 14 0.846 (0.345 to 2.074) 11 0.096 (0.009 to 0.986)
c
Log10 (JCV DNA in plasma) (copies/mL) 3 N/A
a 0 N/A
Log10 (JCV DNA in urine) (copies/mL) 8 1.513 (0.567 to 4.040) 5 1.494 (0.237 to 9.403)
This table reflects ordinal logistic regression on variables of interest at baseline and change from baseline to week 4. Odds ratios are given between
patients who deteriorated on the KPSI score at week 16 compared with baseline vs those who did not. If no values were available at week 16, those from
week 12 were used. Decrease of JCV DNA load in CSF was the only variable significantly associated with lack of clinical deterioration (p=0.015)
ATP adenosine triphosphate, CI confidence interval, CSF cerebrospinal fluid, EDSS Expanded Disability Status Scale, FACS fluorescence-activated
cell sorter, Gd+ gadolinium enhancing, HIV human immunodeficiency virus, JCV JC virus, KPSI Karnofsky Performance Scale Index, LOCF last
observation carried forward, LRT likelihood ratio test, N/A not applicable for testing under this condition (test did not provide any meaningful data),
OR odds ratio, PCR polymerase chain reaction, SDMT Symbol Digit Modality Test, VAS Visual Analogue Scale
aMaximum likelihood modeling was unsuitable due to data separation issues
b Before rounding to three digits after the decimal, the lower limit of the CI was slightly less than 1.000 and the upper limit of the CI was slightly
greater than 1.000
c For every unit increased in JCV load, the odds of improvement are 0.096 for no deterioration vs deterioration
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limit the power to demonstrate improved mortality in studies
such as this one because it is likely to induce prompt immune
reconstitution in most patients with PML.
This trial also underscores the specific challenges of
recruiting for a randomized study that uses a commercially
available drug. In the face of a potentially fatal disease,
patients, families, and clinicians might be uncomfortable
with a randomized trial and highly motivated to try the
active treatment without demanding efficacy or toxicity data
to support this decision.
Our study is too small to definitively rule out mefloquine
activity against PML, but given the inability to find any
evidence of activity in this study, we would not advocate
empiric use of this therapy for PML patients. The findings
from our study support the use of change in JCV DNA in the
CSF, as early as 4 weeks into treatment, as a marker of
clinical outcome in patients with PML. This may be helpful
for management of PML patients, as well as in the design
and conduct of potential future treatment trials in this
population.
Change from baseline to week 16
Change from baseline to week 4
Change from baseline to week 8
−3 −2 −1 0 1 2 3
−3 −2 −1 0 1 2 3
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Fig. 3 Correlation between
KPSI change from baseline to
16 weeks and log10 JCV DNA
load (in CSF) at baseline (a)
and change to weeks 4, 8, and
16 (b–d) (with LOCF from
week 12). CSF cerebrospinal
fluid, JCV JC virus, KPSI
Karnofsky Performance Scale



































Fig. 4 Mean (± SD) KPSI scores in all HIV-positive patients
(HAART-naïve and history of HAART groups combined). HIV-nega-
tive patients not included in analysis. Patients on SOC who opted to
receive mefloquine at week 4 were not counted in the week 8 results.
Asterisk No data for SOC for this time point. HAART highly active
antiretroviral therapy, HIV human immunodeficiency virus, KPSI



































Fig. 5 Mean (±SD) EDSS scores in all HIV-positive patients
(HAART-naïve and history of HAART groups combined). HIV-nega-
tive patients not included in analysis. Patients who opted to receive
mefloquine at week 4 were not counted in the week 8 results. Asterisk
No data for SOC for this time point. EDSS Expanded Disability Status
Scale, HAART highly active antiretroviral therapy, HIV human immu-
nodeficiency virus, SOC standard of care
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